ArticleInsights into imaging2026
A contrast-enhanced CMR-based risk score integrating microvascular obstruction and intramyocardial hemorrhage extent for prognostic evaluation.
Article in Insights into imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesThis study aims to compare the prognostic value of the extent of microvascular obstruction (MVO) combined with intramyocardial hemorrhage (IMH) for major adverse cardiovascular events (MACE) in patients with STEMI. MATERIALS AND
methodsWe analyzed 568 STEMI patients in this retrospective multicenter study. Microvascular injury was visualized using late gadolinium enhancement for MVO, and T2* mapping and T2-weighted cardiovascular magnetic resonance imaging for IMH. The Youden index was used as the cutoff value to divide the study population into four groups. The Eitel CMR risk score, Glasgow CMR risk score, and GRACE (Global Registry of Acute Coronary Events) score were used as references to form Scores 1 and 2. Score 3 included LVEF ≤ 45%, MVO > 1.06% LV, IMH > 0.47% LV, and the GRACE score.
resultsDuring a median follow-up of 3.1 years (IQR: 1.7-5.0 years), 108 patients (19%) experienced MACE. Event rates increased stepwise across groups (8.8% to 58.3%). The combination of MVO > 1.06% LV and IMH > 0.47% LV emerged as the strongest predictor of MACE (HR: 9.646, 95% CI: 6.327-14.705 [p < 0.001]). Score 3 (integrating GRACE score, LVEF, and quantitative MVO and IMH) demonstrated improved predictive performance for MACE compared to the GRACE score (AUC: 0.748), Score 1 (AUC: 0.825), and Score 2 (AUC: 0.802), achieving an AUC of 0.853.
conclusionOur approach integrates quantitative information on MVO and IMH into a risk score that shows better prognostic value than established risk scores. KEY POINTS: Question Current prognostic tools for ST-elevation myocardial infarction patients lack quantitative combined assessment of microvascular obstruction and intramyocardial hemorrhage, limiting precise risk stratification after reperfusion. Findings A novel cardiac magnetic resonance score integrating quantitative microvascular obstruction and intramyocardial hemorrhage extent achieved 0.853 area under the curve for major adverse cardiovascular events. Critical Relevance Statement This study develops a quantitative cardiac magnetic resonance risk score by integrating microvascular obstruction and intramyocardial hemorrhage, offering improved prognostic value for major adverse cardiovascular events in ST-elevation myocardial infarction patients over established clinical scores.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.